Published in CNS Oncol on November 01, 2012
YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol (2007) 8.11
Hippo signaling in organ size control. Genes Dev (2007) 6.29
Hippo signaling: growth control and beyond. Development (2011) 5.25
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev (2009) 2.58
Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature (2005) 2.33
Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci U S A (2011) 2.08
Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res (2009) 2.05
A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J Biochem (2011) 2.00
Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene (2004) 1.61
Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res (2012) 1.58
Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog (2007) 1.44
The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia (2008) 1.23
The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int J Gastrointest Cancer (2006) 1.14
Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med (2009) 1.14
Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol (2011) 1.10
Quit your YAPing: a new target for cancer therapy. Genes Dev (2012) 1.08
Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res (2012) 0.86
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A (2002) 4.45
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res (2011) 3.36
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci U S A (2003) 2.64
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell (2013) 2.62
Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci U S A (2009) 2.57
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res (2003) 2.55
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A (2005) 2.38
A mouse atlas of gene expression: large-scale digital gene-expression profiles from precisely defined developing C57BL/6J mouse tissues and cells. Proc Natl Acad Sci U S A (2005) 2.35
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res (2002) 1.81
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res (2005) 1.75
Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg (2012) 1.60
Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer (2008) 1.54
A survey of glioblastoma genomic amplifications and deletions. J Neurooncol (2009) 1.52
Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol (2012) 1.51
CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A (2009) 1.51
A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest (2004) 1.48
Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun (2008) 1.45
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res (2006) 1.41
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med (2013) 1.40
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget (2011) 1.39
Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res (2005) 1.33
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget (2013) 1.31
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell (2013) 1.28
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget (2013) 1.28
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol (2011) 1.26
PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immun (2007) 1.21
The impact of SNPs on the interpretation of SAGE and MPSS experimental data. Nucleic Acids Res (2004) 1.19
Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene (2004) 1.18
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther (2009) 1.18
Exomic sequencing of four rare central nervous system tumor types. Oncotarget (2013) 1.17
Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene (2003) 1.14
DDIT3, STT3A (ITM1), ARG2 and FAM129A (Niban, C1orf24) in diagnosing thyroid carcinoma: variables that may affect the performance of this antibody-based test and promise. Mod Pathol (2013) 1.12
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther (2010) 1.12
Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutat (2006) 1.12
Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res (2006) 1.07
Oncogenomics and the development of new cancer therapies. Nature (2004) 1.06
Glioblastoma cell growth is suppressed by disruption of Fibroblast Growth Factor pathway signaling. J Neurooncol (2009) 1.04
Identification of astrocytoma associated genes including cell surface markers. BMC Cancer (2004) 1.04
PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. J Neurooncol (2006) 1.02
Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing. Genome Biol (2010) 1.01
Re-expression of ABI3-binding protein suppresses thyroid tumor growth by promoting senescence and inhibiting invasion. Endocr Relat Cancer (2008) 1.01
Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. Cancer Immun (2004) 1.00
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Curr Opin Oncol (2012) 1.00
Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res (2013) 0.98
Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol (2013) 0.98
OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res (2012) 0.98
Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res (2010) 0.97
MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer (2010) 0.96
Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun (2008) 0.96
Coexpression of neuronatin splice forms promotes medulloblastoma growth. Neuro Oncol (2008) 0.96
Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res (2008) 0.95
Identification of microbial DNA in human cancer. BMC Med Genomics (2009) 0.95
Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun (2006) 0.95
Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun (2008) 0.94
c-Myc promoter activation in medulloblastoma. Cancer Res (2003) 0.93
Splicing factors are differentially expressed in tumors. Genet Mol Res (2004) 0.93
Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun (2007) 0.92
Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Med Genomics (2013) 0.91
Establishment of a human glioblastoma stemlike brainstem rodent tumor model. J Neurosurg Pediatr (2010) 0.91
Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in astrocytoma motility. J Biol Chem (2006) 0.91
A robust approach to enhance tumor-selective accumulation of nanoparticles. Oncotarget (2011) 0.91
Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res (2007) 0.91
Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome. PLoS One (2013) 0.91
Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res (2013) 0.90
Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer. Clin Cancer Res (2008) 0.90
Targeting the AKT pathway in glioblastoma. Curr Pharm Des (2011) 0.90
Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. Mol Cancer (2011) 0.89
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS One (2012) 0.89
Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immun (2009) 0.89
ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. Clin Cancer Res (2008) 0.88
A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. Mol Cancer (2007) 0.87
SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. Cancer Lett (2009) 0.87
Differential evolution of MAGE genes based on expression pattern and selection pressure. PLoS One (2012) 0.87
ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence. BMC Cancer (2011) 0.86
Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. Neuro Oncol (2010) 0.86
PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression. J Clin Endocrinol Metab (2010) 0.86
Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res (2012) 0.86
Caveolin-1, caveolae, and glioblastoma. Neuro Oncol (2012) 0.86
Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. Exp Hematol (2009) 0.85
Noninvasive imaging of infection after treatment with tumor-homing bacteria using Chemical Exchange Saturation Transfer (CEST) MRI. Magn Reson Med (2013) 0.84
Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches. J Hepatobiliary Pancreat Sci (2014) 0.83